CAMBRIDGE, Mass.--(BUSINESS WIRE)--Idera Pharmaceuticals, Inc. (Nasdaq: IDRA) today announced the presentation of data from its multiple-dose Phase 1 clinical trial of IMO-3100 in healthy subjects. The trial was designed to evaluate the safety and mechanism of action of IMO-3100, a Toll-like Receptor (TLR) 7 and TLR9 dual antagonist that is Idera’s lead drug candidate in development to treat autoimmune and inflammatory diseases. In the trial, IMO-3100 was well tolerated over the four weeks of treatment. In addition, target engagement of TLR7 and TLR9 was observed, confirming the intended mechanism of action of IMO-3100. The presentation (Abstract #333) entitled “IMO-3100, a novel toll-like receptor antagonist for autoimmune and inflammatory diseases: safety and pharmacodynamics in a multiple-dose Phase 1 clinical trial” is being made today at the Keystone Symposia meeting “Immunoregulatory Networks” being held in Breckenridge, Colorado from April 1-6, 2011.
